Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Phillips

Showing results (191-200 of 287) with videos related to

Pageof 29
Sort By:
Lancet (London, England)|December 11, 2007
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips, Clifford Leen, Alan Wilson, et al.
AIDS (London, England)|July 12, 2013
Associations between immune depression and cardiovascular events in HIV infectionCaroline A Sabin, Lene Ryom, Stephane De Wit, et al.
AIDS (London, England)|January 8, 2013
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease eventsAntonella d'Arminio Monforte, Peter Reiss, Lene Ryom, et al.
AIDS (London, England)|January 9, 2010
Late diagnosis in the HAART era: proposed common definitions and associations with mortality, Caroline A Sabin, Achim Schwenk, et al.
AIDS (London, England)|October 14, 2017
Abacavir use and risk of recurrent myocardial infarctionCaroline A Sabin, Lene Ryom, Antonella d'Arminio Monforte, et al.
The Lancet. HIV|September 14, 2025
Dynamic choice HIV prevention with long-acting injectable cabotegravir pre-exposure prophylaxis in east, central, southern, and west Africa: a cost-effectiveness modelling analysisAndrew N Phillips, Matthew D Hickey, Starley B Shade, et al.
AIDS (London, England)|June 24, 2003
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD studyNina Friis-Møller, Rainer Weber, Peter Reiss, et al.
BMC Health Services Research|February 7, 2026
"We carried her in a wheelbarrow to the clinic": process evaluation of the AMETHIST intervention combining microplanning with self-help groups to improve HIV prevention and treatment among female sex workers in ZimbabweFortunate Machingura, Gracious Madimutsa, Memory Makamba, et al.
AIDS (London, England)|June 26, 2007
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie, Loveleen K Bansi, Caroline A Sabin, et al.
Lancet (London, England)|April 5, 2008
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration, Caroline A Sabin, Signe W Worm, et al.
Pageof 29

Showing results (191-200 of 287) with videos related to

Sort By:
Pageof 29
Lancet (London, England)|December 11, 2007
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips, Clifford Leen, Alan Wilson, et al.
AIDS (London, England)|July 12, 2013
Associations between immune depression and cardiovascular events in HIV infectionCaroline A Sabin, Lene Ryom, Stephane De Wit, et al.
AIDS (London, England)|January 8, 2013
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease eventsAntonella d'Arminio Monforte, Peter Reiss, Lene Ryom, et al.
AIDS (London, England)|January 9, 2010
Late diagnosis in the HAART era: proposed common definitions and associations with mortality, Caroline A Sabin, Achim Schwenk, et al.
AIDS (London, England)|October 14, 2017
Abacavir use and risk of recurrent myocardial infarctionCaroline A Sabin, Lene Ryom, Antonella d'Arminio Monforte, et al.
The Lancet. HIV|September 14, 2025
Dynamic choice HIV prevention with long-acting injectable cabotegravir pre-exposure prophylaxis in east, central, southern, and west Africa: a cost-effectiveness modelling analysisAndrew N Phillips, Matthew D Hickey, Starley B Shade, et al.
AIDS (London, England)|June 24, 2003
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD studyNina Friis-Møller, Rainer Weber, Peter Reiss, et al.
BMC Health Services Research|February 7, 2026
"We carried her in a wheelbarrow to the clinic": process evaluation of the AMETHIST intervention combining microplanning with self-help groups to improve HIV prevention and treatment among female sex workers in ZimbabweFortunate Machingura, Gracious Madimutsa, Memory Makamba, et al.
AIDS (London, England)|June 26, 2007
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie, Loveleen K Bansi, Caroline A Sabin, et al.
Lancet (London, England)|April 5, 2008
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration, Caroline A Sabin, Signe W Worm, et al.
Pageof 29